Acitretin Plasma Levels Under Hemodialysis

Günther Hofbauer

Status and phase: Withdrawn; Phase 4

Conditions: Carcinoma, Squamous Cell

Treatments: Drug: Chemopreventive application (Acitretin)

Study type: Interventional

Funder types: Other

Identifiers

NCT00488384

2007DR2065 EK674

Details and patient eligibility

About

Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year.

Full description

Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year. Plasma levels of acitretin will be monitored and influence of hemodialysis on acitretin plasma levels will be determined. Number of in-situ or invasive squamous cell carcinoma of the skin cases will be determined.

• Trial with medicinal product

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Hemodialyis patients with at least one case of in-situ or invasive squamous cell carcinoma of the skin

Exclusion criteria

• Hepatopathy
• Pregnancy

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

a

Other group

Description:

single arm only. Only open label treatment anticipated

Treatment:

Drug: Chemopreventive application (Acitretin)